Alderley Park, Cheshire
Our research and development site Alderley Park, in the north-west of England, is our global lead centre for cancer research.
Employing approximately 2,900 people, including some of the world’s most skilled and experienced science professionals, Alderley Park is renowned for the discovery and development of innovative new medicines. Opening more than 40 years ago, Alderley Park has a rich heritage of important advancements in medical treatments, with a number of anti-cancer treatments having been developed at the site. As the lead centre for cancer research, Alderley Park currently houses the global Advanced Lead Discovery Centre, which includes innovative facilities to assist with the drug discovery process, in addition to Oncology discovery and early development capabilities (Oncology Innovative Medicines). Alderley Park is also home to employees within our global medicines development function, who are responsible for the late stage development of our pipeline (products in phase III development). The significant majority of these R&D activities will transition to our new purpose-built global R&D centre in Cambridge, with approximately 1,600 roles re-locating from Alderley Park over the next three years.
As announced in March 2014, AstraZeneca has sold Alderley Park to Manchester Science Parks (MSP), a Greater Manchester based public-private partnership and science park operator. The new owners plan to build on the Park’s heritage of scientific innovation, ensuring that the 400 acre site remains a life science and biotechnology campus. To date, the BioHub has 38 high calibre companies employing more than 200 people. We expect, in the future, further collaborations will be established with companies in this BioHub.
AstraZeneca will remain a key tenant at Alderley Park with around 700 staff in non-R&D roles.